A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels
CONCLUSIONS: The evolocumab LDL-C-lowering effect observed in clinical trials was confirmed in clinical practice in Sweden, particularly in patients also treated with oral LLT. During follow-up, adherence to and persistence with evolocumab were high, with stable reduced levels of LDL-C during observation.PMID:38327639 | PMC:PMC10845886 | DOI:10.48101/ujms.v129.9618
Source: Upsala Journal of Medical Sciences - Category: General Medicine Authors: Maria K Svensson Stefan James Annica Ravn-Fischer Guillermo Villa Lovisa Schalin Thomas Cars Stefan Gustafsson Emil Hagstr öm Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Clinical Trials | General Medicine | Heart | Study | Sweden Health